Short communication (Scientific journals)
Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome
Heinrichs, C.; Vis, H. L.; Bergman, P. et al.
1993In Clinical Endocrinology, 38 (6), p. 647-651
Peer Reviewed verified by ORBi
 

Files


Full Text
Heinrichs_Effects17MonthsTreatment_1993.pdf
Publisher postprint (3.5 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Bone density; Child; Humans; Growth disorders; Growth hormone; Recombinant proteins; Syndrome; Time factors
Abstract :
[en] Objective: With the availability of recombinant insulin-like growth factor-I (recIGF-I), it was possible to study whether this peptide could promote growth without noticeable side-effects in patients with growth hormone insensitivity syndrome (Laron syndrome). We report data obtained before and during 17 months treatment using recIGF-I, 40 μg/kg s.c. twice a day, in two Lebanese siblings. Patients: The boy and the girl showed very short stature (-6.8 and -6.1 SDS), high GH (79 and 147 IU/l), low plasma IGF-I (0.12 and 0.18 U/ml) and undetectable GH binding protein. Height velocities were 4.3 and 3.8 cm/year before treatment which started at 8.4 and 6.8 years of age, respectively. Results: After 1-8 weeks of therapy, biological evidence of IGF-I effect was obtained from reduction in serum GH and increase in procollagen-I. During the first 6 months of treatment, height velocity increased to 7.8 and 8.4 cm/year without any clinical evidence of side-effects. Between 6 and 12 months, growth response decreased to 6.6 and 6.3 cm/year. Between 12 and 17 months, growth rate returned to pretreatment values. Changes in bone mineral density paralleled growth response and bone maturation ed by 1.5 and 2.0 years during the first 12 months of treatment. Daily assessment of blood sugar showed asymptomatic low values (< 2.8 mM/l) in 11/730 and 22/730 measurements in the boy and the girl, respectively. Conclusions: Treatment of two patients with growth hormone insensitivity syndrome using 40 μg/kg of IGF-I twice a day resulted in increased linear bone growth and bone mineralization as well as increased bone maturation without remarkable adverse events. After 1 year of therapy, growth response could no longer be observed in these two patients.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Heinrichs, C.
Vis, H. L.
Bergman, P.
Wilton, P.
Bourguignon, Jean-Pierre ;  Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome
Publication date :
1993
Journal title :
Clinical Endocrinology
ISSN :
0300-0664
eISSN :
1365-2265
Publisher :
Blackwell, Oxford, United Kingdom
Volume :
38
Issue :
6
Pages :
647-651
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 25 May 2021

Statistics


Number of views
51 (1 by ULiège)
Number of downloads
85 (1 by ULiège)

Scopus citations®
 
22
Scopus citations®
without self-citations
18
OpenCitations
 
20

Bibliography


Similar publications



Contact ORBi